Allarity Therapeutics (ALLR) Competitors $1.55 -0.07 (-4.32%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.58 +0.02 (+1.61%) As of 10/3/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR vs. ADAG, COYA, WHWK, EQ, CNTB, IFRX, ZYBT, QNCX, ABOS, and MGXShould you be buying Allarity Therapeutics stock or one of its competitors? The main competitors of Allarity Therapeutics include Adagene (ADAG), Coya Therapeutics (COYA), Whitehawk Therapeutics (WHWK), Equillium (EQ), Connect Biopharma (CNTB), InflaRx (IFRX), Zhengye Biotechnology (ZYBT), Quince Therapeutics (QNCX), Acumen Pharmaceuticals (ABOS), and Metagenomi (MGX). These companies are all part of the "pharmaceutical products" industry. Allarity Therapeutics vs. Its Competitors Adagene Coya Therapeutics Whitehawk Therapeutics Equillium Connect Biopharma InflaRx Zhengye Biotechnology Quince Therapeutics Acumen Pharmaceuticals Metagenomi Adagene (NASDAQ:ADAG) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Do institutionals and insiders have more ownership in ADAG or ALLR? 9.5% of Adagene shares are owned by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 0.1% of Allarity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ADAG or ALLR? Adagene has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Allarity Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Is ADAG or ALLR more profitable? Adagene's return on equity of 0.00% beat Allarity Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AdageneN/A N/A N/A Allarity Therapeutics N/A -173.31%-102.57% Does the media refer more to ADAG or ALLR? In the previous week, Adagene had 2 more articles in the media than Allarity Therapeutics. MarketBeat recorded 4 mentions for Adagene and 2 mentions for Allarity Therapeutics. Adagene's average media sentiment score of 0.69 beat Allarity Therapeutics' score of 0.66 indicating that Adagene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagene 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ADAG or ALLR? Adagene presently has a consensus price target of $7.00, suggesting a potential upside of 253.54%. Allarity Therapeutics has a consensus price target of $9.25, suggesting a potential upside of 496.77%. Given Allarity Therapeutics' higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Adagene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagene 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, ADAG or ALLR? Allarity Therapeutics has lower revenue, but higher earnings than Adagene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdagene$100K933.17-$33.42MN/AN/AAllarity TherapeuticsN/AN/A-$24.51MN/AN/A SummaryAdagene beats Allarity Therapeutics on 10 of the 13 factors compared between the two stocks. Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALLR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALLR vs. The Competition Export to ExcelMetricAllarity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.51M$3.36B$6.12B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E RatioN/A22.2886.9626.71Price / SalesN/A461.37605.41130.98Price / CashN/A47.8637.9061.31Price / Book0.969.9312.556.55Net Income-$24.51M-$52.80M$3.31B$277.50M7 Day Performance-1.90%5.22%4.28%2.42%1 Month Performance-21.32%10.61%6.90%8.63%1 Year Performance-11.93%25.03%70.54%31.60% Allarity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALLRAllarity Therapeutics2.9848 of 5 stars$1.55-4.3%$9.25+496.8%-11.9%$22.51MN/A0.0010Short Interest ↓ADAGAdagene2.7783 of 5 stars$2.02+2.8%$7.00+247.4%-11.6%$92.38M$100K0.00260Short Interest ↑COYACoya Therapeutics2.7065 of 5 stars$5.66+3.1%$16.50+191.5%-16.0%$91.82M$423.45K-4.566Analyst ForecastWHWKWhitehawk TherapeuticsN/A$1.92-1.0%N/AN/A$91.43M$21.60M-32.0021Positive NewsEQEquillium0.556 of 5 stars$1.46-2.7%$1.00-31.5%+53.8%$89.25M$41.10M-2.6140CNTBConnect Biopharma3.8446 of 5 stars$1.32-16.6%$7.00+431.5%+5.7%$88.04M$26.03M0.00110Short Interest ↓IFRXInflaRx2.2546 of 5 stars$1.37+5.4%$6.20+352.6%+1.3%$87.27M$180K-1.7160Short Interest ↑ZYBTZhengye BiotechnologyN/A$2.19+19.0%N/AN/A$86.79M$186.36M0.00278QNCXQuince Therapeutics3.4082 of 5 stars$1.61flat$8.14+405.8%+109.3%$86.48MN/A-1.4860News CoverageABOSAcumen Pharmaceuticals3.2289 of 5 stars$1.58+11.3%$7.00+343.0%-27.0%$86.01MN/A-0.6920News CoveragePositive NewsGap UpMGXMetagenomi3.4948 of 5 stars$2.30+0.4%$10.00+334.8%+31.2%$85.95M$52.29M-0.97236News Coverage Related Companies and Tools Related Companies Adagene Alternatives Coya Therapeutics Alternatives Whitehawk Therapeutics Alternatives Equillium Alternatives Connect Biopharma Alternatives InflaRx Alternatives Zhengye Biotechnology Alternatives Quince Therapeutics Alternatives Acumen Pharmaceuticals Alternatives Metagenomi Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALLR) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts